What is Leerink Partnrs' Forecast for AUPH Q1 Earnings?

Key Points

• Leerink Partners forecasts Aurinia Pharmaceuticals (AUPH) to post $0.15 earnings per share for Q1 2026, with full-year estimates of $0.65 EPS for 2026 and $0.77 EPS for 2027.
• Aurinia's recent earnings report revealed a net margin of 23.31% and a revenue of $70.01 million, exceeding analyst expectations of $64.27 million.
• Institutional investors have recently increased their stakes in Aurinia, with notable increases from GF Fund Management and Tower Research Capital.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP - Stock analysts at Leerink Partnrs issued their Q1 2026 EPS estimates for shares of Aurinia Pharmaceuticals in a report issued on Thursday, July 31st. Leerink Partnrs analyst J. Schwartz anticipates that the biotechnology company will post earnings per share of $0.15 for the quarter. The consensus estimate for Aurinia Pharmaceuticals' current full-year earnings is $0.11 per share. Leerink Partnrs also issued estimates for Aurinia Pharmaceuticals' Q2 2026 earnings at $0.17 EPS, Q3 2026 earnings at $0.16 EPS, Q4 2026 earnings at $0.18 EPS, FY2026 earnings at $0.65 EPS and FY2027 earnings at $0.77 EPS.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.01). Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The business had revenue of $70.01 million for the quarter, compared to analysts' expectations of $64.27 million.

Several other research firms also recently weighed in on AUPH. HC Wainwright restated a "buy" rating and set a $17.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Royal Bank Of Canada lifted their price target on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a report on Friday.

Aurinia Pharmaceuticals Stock Performance

NASDAQ:AUPH opened at $10.49 on Monday. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. The firm has a 50-day moving average price of $8.35 and a two-hundred day moving average price of $8.14. Aurinia Pharmaceuticals has a twelve month low of $5.20 and a twelve month high of $10.67. The company has a market capitalization of $1.38 billion, a P/E ratio of 24.40 and a beta of 1.23.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $27,000. Tower Research Capital LLC TRC grew its holdings in shares of Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after buying an additional 2,635 shares in the last quarter. Vermillion & White Wealth Management Group LLC purchased a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $31,000. GAMMA Investing LLC boosted its position in shares of Aurinia Pharmaceuticals by 56.1% in the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock worth $39,000 after acquiring an additional 1,744 shares during the last quarter. Finally, MAI Capital Management acquired a new stake in shares of Aurinia Pharmaceuticals in the first quarter worth approximately $39,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.